Boston Scientific Corp (NYSE:BSX<\/strong>) is among the best medical AI stocks to buy now<\/strong>. Piper Sandler reaffirmed its Overweight rating on Boston Scientific Corp (NYSE:BSX) stock on April 6. This followed the release of the Champion-AF study results of Boston Scientific\u2019s Watchman heart implant. The firm renewed its bullish stance on Boston Scientific stock after hosting a discussion with a doctor who performs high-volume heart implants. That discussion centered on cardiac device usage.<\/p>\n Copyright: mikkolem \/ 123RF Stock Photo<\/p>\n Piper Sandler expects Watchman sales to increase 20% annually for the next several years. It added that this should contribute around 200 basis points to Boston Scientific\u2019s topline growth.<\/p>\n In the Champion-AF study, Boston Scientific\u2019s Watchman heart implant met all primary and secondary endpoints regarding safety and efficiency. That study evaluated the Watchman device as a first-line treatment option for stroke risk reduction. There are more than 59 million people globally with a heart rhythm disorder who could benefit from the Watchman implant.<\/p>\n In 2025, Boston Scientific\u2019s net sales grew 19.9% to $20 billion, and adjusted EPS came to $3.06, compared to $2.51 in the prior year. Boston Scientific CEO Mike Mahoney said 2025 was another exceptional year for the company, noting that they exceeded their goals. The company expects the growth to continue, forecasting topline growth of at least 10.5% in 2026.<\/p>\n Boston Scientific Corp (NYSE:BSX) is an American multinational biotechnology and biomedical engineering company. It makes medical devices used to address cardiovascular, respiratory, and neurological conditions. Boston Scientific was founded in 1979 and is based in Massachusetts.<\/p>\n While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong>.<\/p>\n<\/div>\n<\/div>